Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study F. Valenzuela, C. de la Cruz Fernandez, R.L. Galimberti, S. Gürbüz, M. McKean-Matthews, L. Goncalves, R. Romiti

Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis A. Azevedo, T. Torres

Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study E. Daudén, R.M. Pujol, J.L. Sánchez-Carazo, J. Toribio, F. Vanaclocha, L. Puig, M. Yébenes, E. Sabater, M.A. Casado, M.T. Caloto, B. Aragón